New startup ideas · Health and bio · Healthcare and bio
startup idea
Corelane
A spot market for wet-lab experiments that software agents can order by API.
Corelane is a marketplace where pharma and AI-bio R&D teams buy idle bench and instrument time from academic core facilities, contract labs and instrument-rich startups.
- Marketplace
- Enterprise
- $100B+ market
- Creates a new category
- US first
4/5
venture judge
1
similar startups, last 2 years (28 all-time)
97%
of 4 nearest real companies still alive
yes
1 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$700 · 4 weeks · 25 prospects
For $700 in 4 weeks, prove that seed-stage AI-bio teams will prepay a posted price for a brokered core-facility run, and that university facilities can actually transact fast enough to supply them.
Riskiest assumption · A seed-stage AI-bio team will prepay a posted price to book a defined instrument run at a university core facility it has no relationship with, instead of routing the job through its existing CRO or academic contacts.
1Focus group: who and where
Founder or head of platform at a seed-stage AI-bio company, 2-15 people and under $10M raised, whose roadmap needs mass spec or cryo-EM data this quarter and who owns neither instrument, currently waiting on a collaborator's queue or a CRO quote that took two weeks to arrive.
where to find 25 · Bits in Bio, the Slack community where bio-software founders already ask where to get runs done; the YC Startup Directory filtered to 2024-2026 bio companies, including cohort-mates of Omanta, 10x Science and Rasyn, emailed directly; SLAS (Society for Laboratory Automation and Screening) events and its startup track; for the supply-side check, the ABRF (Association of Biomolecular Resource Facilities) directory of US university core facilities.
2Sell first, build later
A fixed-scope instrument run at a posted price: named assay, sample count, turnaround in business days and a defined data format, executed at a US university core facility, with the first slots 3 weeks out.
the ask · $1,800-2,900 per run depending on the assay, with $250 of it paid today as a refundable slot deposit
a real yes · A real yes is the $250 deposit paid and the balance authorized at booking confirmation; compliments, requests for a free pilot run, and offers to introduce their PI friends are not a yes.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Prepaid run pre-sale
$300 · 12 days
Build a one-page rate card with three fixed-scope offers, for example 24-sample LC-MS/MS proteomics at $2,900 with mzML data in 10 business days, and a 4-hour cryo-EM screening session at $1,800. The founder emails and DMs 25 buyers from Bits in Bio and the YC directory, books calls, and asks each caller to hold a dated slot with a $250 refundable deposit.
keep going if · 10 of 25 reply, 5 book a call, and 3 of those pay the $250 deposit
2. Core facility listing test
$0 · 10 days
Email 20 core facility directors from the ABRF directory with one question: will you accept a paid external order at your posted industry rate, invoiced to a company, with work starting inside 2 weeks. Log who can transact, who needs an IP or accounting review first, and how long that review takes.
keep going if · 5 of 20 confirm in writing they can invoice an external company and start inside 2 weeks; fewer than 2 means the card's supply risk is real
3. Broker one run end to end
$400 · 15 days
Match one deposit-paying buyer to one confirmed facility and run the whole order by hand: quote, sample shipping, scheduling, data delivery in the promised format, balance collected. The founder is the API for this one run.
keep going if · 1 run goes from order to delivered data within 15 business days at full posted price, with the balance paid
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$250
per prospect, refundable
how · A $250 refundable slot reservation paid by card or ACH from a checkout on the rate card page; a checkout fits this buyer because startup founders pay small amounts on a company card the same day, where an invoice or PO would stall a $250 charge. The founder countersigns a one-page slot confirmation naming the facility, assay, date and posted price. set up: Stripe Invoicing ↗
what it reserves · A dated instrument slot for the named assay at the posted price, with the data format guaranteed and the deposit credited to the run balance
refund · Refunded in full any time before samples ship, and automatically if the slot is not confirmed within 10 business days.
target · 3 deposits from 25 prospects within 3 weeks
Go: build it if
3 of 25 buyers pay the $250 deposit, at least 5 of 20 core facilities confirm they can invoice an external company inside 2 weeks, and 1 brokered run delivers data within 15 business days.
Kill: stop if
Fewer than 2 deposits after 25 contacts and 10 calls, or fewer than 2 of 20 facilities able to transact with an outside company inside 30 days; either side failing kills the spot market.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
You are running a bio platform without owning a mass spec, which means every proteomics run waits in someone else's queue. I am booking fixed-scope runs at US university core facilities at posted prices: 24-sample LC-MS/MS for $2,900, mzML data back in 10 business days, or a 4-hour cryo-EM screening session for $1,800. A $250 refundable deposit holds a dated slot. Do you have 20 minutes this week to look at the rate card and pick one?
landing page
Order instrument runs like compute: posted price, fixed turnaround, clean data $1,800-2,900 per run; a $250 refundable deposit holds a dated slot. Reserve your run slot.
deposit terms
Your $250 reserves a dated instrument slot for the assay on your order at the posted price, and is credited against the run balance. It is fully refundable any time before your samples ship, and refunded automatically if we cannot confirm your slot within 10 business days. First slots run 3 weeks from booking.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
84
Idea Score, 0-100 · raw 52.3 x 1.61
Warm
competition: more crowded than 20% of ideas · headwind x0.90
+0.8
government priorities, secondary (1 matching grants)
Trend
60
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)23
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst50
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
60
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis80
- Neighbours still alive6
- Technologist judge25
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were spot, wet-lab, experiments, order, marketplace, pharma, ai-bio, buy.
The idea in full
- What
- Corelane is a marketplace where pharma and AI-bio R&D teams buy idle bench and instrument time from academic core facilities, contract labs and instrument-rich startups. Every listing is normalized into a machine-readable protocol schema with a price, a turnaround and a data format, so a research team or its automated planner can order a binding assay, a cryo-EM session or a proteomics run the way it orders compute. Corelane owns the schema, the escrow and the quality history; it owns no labs.
- Why now
- The 2026 cohort is full of teams whose product is experiment throughput rather than a drug: Omanta (yc S26) pitches a research lab for one, 10x Science (yc W26) an AI-native platform for protein characterization and Rasyn (yc S26) a general intelligence for chemistry, and 126 new companies entered this cluster in 2024 alone, all of them buying bench time from someone.
- Wedge: first customer and entry point
- Ten US university core facilities with visible idle time on mass spec and cryo-EM, matched to the 30-odd seed-stage AI-bio teams in this cluster who cannot justify buying the instrument.
- Path to 100x
- Global pharma R&D spend is above $100B a year and a large share is outsourced experiment by experiment through relationship sales with no posted price; a marketplace that becomes the default API surface for ordering experiments creates the category and takes a fee on flow. Exclusive listing deals with the highest-value instrument sites give a distribution moat, and once agents are wired to one protocol schema, switching means rewriting the planner.
- Ceiling
- Pharma keeps buying experiments through master service agreements with three preferred CROs, leaving Corelane the long tail of small orders and a take rate too thin to reach $1B.
- Closest real companies, as the generator saw them
- Harbor is an AI-native CRO that runs trial operations itself; Corelane never delivers the work, it prices and routes it. Omanta automates one team's own lab rather than pooling other people's capacity.
- Main risk
- Core facilities cannot sell externally at speed because of university accounting and IP review, so supply never becomes liquid enough for a spot price.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Capital-light marketplace owning the protocol schema that automated planners write against, taking a fee on $100B+ of outsourced experiment flow.
Bootstrapper
3/5
Capital-light and asset-free, but university accounting and IP review make core-facility supply slow to become liquid enough to price.
Operator
2/5
Pharma buys experiments under master service agreements with three preferred CROs, and university accounting blocks the supply side from listing.
Technologist
2/5
Corelane owns no labs, so the protocol schema and escrow are a listing layer any well-funded CRO aggregator rebuilds.
Risk
3/5
Capital-light and unregulated with no lab ownership, but supply depends on university accounting and IP review that can stall listings indefinitely.
trends
3/5
Machine-readable experiment ordering aligns with 2026's agent-to-service procurement turn, but the card's own why-now is only cohort composition, not a dated shift.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (spot, wet-lab, experiments, order, marketplace, pharma, ai-bio, buy): 28 all-time, 1 from the last two years. Same matching as Idea Check.
Move Loot is the most convenient and economical way to buy and sell…
Mavi.io provides a platform that integrates retail directly into vehicle dashboards, enabling users to discover, purchase, and receive products from major retailers while on the go.
AI powered reconciliation for high-volume payments companies
B2B Marketplace for Steel Raw Materials
On-demand food delivery for Africa
A direct to consumer marketplace and influencer network for brands
Super Hyperlocal Marketplace for SMEs in Indonesia
The platform for buying, selling and managing residential construction
Where restaurants in Africa buy food supplies
B2B marketplace for construction material in Brazil.
Group buy for groceries in African cities.
The best way for any business to offer delivery.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
1
grants and programs matching the idea
1596
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
119
opportunities open now in the sector
- Low-cost and high efficiency DNA-based Reverse Genetics Platforms for manufacturing RNA virus products.awardhigh relevance
NIH / NCHHSTP · SBIR phase I · $279K · posted 2025-09-30
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 125 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 441 YC companies here: 6 acquired, 6 shut down, 44 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Real engineering
- Go-to-market
- Founder-led sales
- Moat
- Distribution moat
- Geography
- US first
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.